Iridium Network Becomes 1st Center In the World to Use RayCare and TrueBeam to Treat a Patient

RaySearch Laboratories AB (publ) announced that Iridium Network in Belgium has treated its first patient using RaySearch’s oncology information system RayCare®* together with a Varian TrueBeam®** linear accelerator. The treatment was successfully carried out on September 2, 2024.

Since its establishment in 2006, Iridium Network has grown to become the largest radiotherapy network in Belgium, providing highly specialized radiation oncology for three hospital networks in the larger region of Antwerp, as well as being a leading expertise center with an international reputation. In total, the network has ten TrueBeam linear accelerators, installed at four sites, treating more than 6,000 patients with radiation therapy each year.

Iridium Network and RaySearch have a close and long-standing collaboration. The network became a clinical partner to RaySearch in late 2015 when it acquired RayStation and has also strongly contributed to the development of RayCare. In 2018 the network became the first hospital in the world to clinically use RayCare, only two months after the release of the system.

Dr. Piet Dirix, Radiation Oncologist, Iridium Network, says: “My team and I are extremely happy to have been part of the journey of developing RayCare to what it is today, a next generation oncology information system designed to incorporate all disciplines of cancer care. We aspire to create one oncology workflow, allowing a seamless experience for both patients and health care professionals.”

As previously announced, the interoperability certificate between RayCare 2024A and TrueBeam was issued in May 2024, and applies to all linear accelerators in the TrueBeam family: TrueBeam, TrueBeam STx, Edge and VitalBeam. And once again, only a couple of months after the announcement, Iridium Network reaches an important milestone for RayCare, becoming the first hospital to take RayCare in clinical use together with TrueBeam.

Prof. Dirk Verellen, Director Medical Physics, Iridium Network, says: “With RayCare we achieve consistency and automation, two factors that play a crucial role in maintaining patient safety, efficiency and quality of care. RayCare strongly contributes to our ability to offer cutting-edge radiation oncology solutions to patients throughout our network.”

Johan Löf, founder and CEO, RaySearch: “RayCare is the result of a strong partnership between industry and clinical experts in developing an integrated oncology information system and I am proud of our long-standing collaboration with Iridium Network. Today, when RayCare was connected with TrueBeam, an important milestone was clinically manifested for our shared commitment to advancing cancer care with the patient in focus.”

* Subject to regulatory clearance in some markets.

** The marks Varian and TrueBeam are trademarks of Varian Medical Systems Inc.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”